Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 23528042)

Published in J Thromb Haemost on June 01, 2013

Authors

E K Waters1, R M Genga, H A Thomson, J C Kurz, R G Schaub, F Scheiflinger, K E McGinness

Author Affiliations

1: Baxter Healthcare Corporation, Cambridge, MA, USA.

Articles by these authors

Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med (1993) 5.71

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology (1998) 4.13

Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost (2010) 1.59

Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. J Thromb Haemost (2009) 1.52

Linked folding and anion binding of the Bacillus subtilis ribonuclease P protein. Biochemistry (2001) 1.41

Magnesium ions are required by Bacillus subtilis ribonuclease P RNA for both binding and cleaving precursor tRNAAsp. Biochemistry (1996) 1.33

Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost (2006) 1.22

Structural and functional studies of the measles virus hemagglutinin: identification of a novel site required for CD46 interaction. Virology (1999) 1.16

IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells (1994) 1.14

IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost (2009) 1.08

Expression, purification and characterization of the recombinant ribonuclease P protein component from Bacillus subtilis. Nucleic Acids Res (1998) 1.07

Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am J Pathol (1996) 1.06

Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood (1996) 1.03

Suppression of aortic atherosclerosis in cholesterol-fed rabbits by purified rabbit interferon. Arteriosclerosis (1990) 1.01

VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost (2009) 1.00

Early events in the formation of a venous thrombus following local trauma and stasis. Lab Invest (1984) 0.99

Recombinant human macrophage colony-stimulating factor in nonhuman primates: selective expansion of a CD16+ monocyte subset with phenotypic similarity to primate natural killer cells. Blood (1996) 0.98

Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrix. J Biomed Mater Res (1994) 0.96

A model of measles virus-induced immunosuppression: enhanced susceptibility of neonatal human PBLs. Nat Med (1996) 0.95

Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation (1999) 0.95

BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie (2012) 0.92

Recombinant soluble p-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine. Circulation (2001) 0.90

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost (2012) 0.89

Acetyl glyceryl ether phosphorylcholine (PAF-acether) and leukotriene B4-mediated neutrophil chemotaxis through an intact endothelial cell monolayer. Biochim Biophys Acta (1984) 0.88

Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood (2001) 0.88

Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost (2011) 0.88

Suppression of experimental atherosclerosis in rabbits by interferon-inducing agents. J Am Coll Cardiol (1984) 0.87

Recombinant human bone morphogenetic protein-2 is superior to demineralized bone matrix in repairing craniotomy defects in rats. J Biomed Mater Res (1994) 0.86

Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost (2002) 0.85

Successful change programs begin with results. Harv Bus Rev (1992) 0.85

Interleukin-1 induced vascular pathology "in vivo": a scanning electron-microscopy study. Agents Actions (1989) 0.84

Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. Crit Rev Immunol (1997) 0.84

Equine endotoxemia: an insight into cause and treatment. J Am Vet Med Assoc (1981) 0.84

The role of recombinant interleukin 11 in megakaryocytopoiesis. Stem Cells (1996) 0.83

Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates. Stem Cells (1996) 0.83

Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin Cancer Res (1997) 0.83

Cloning, expression and functional characterization of the full-length murine ADAMTS13. J Thromb Haemost (2005) 0.82

Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood (1999) 0.82

Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost (2011) 0.81

Pulmonary vascular response during phases of canine heartworm disease: scanning electron microscopic study. Am J Vet Res (1980) 0.81

Renal microthrombosis following endotoxin infusion may be mediated by lipoxygenase products. Circ Shock (1987) 0.81

Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. Thromb Haemost (2001) 0.81

Comparison of lipid accumulation and metabolism in carrageenan-induced granulomas to aorta and blood monocytes of normal and cholesterol-fed rabbits. Exp Mol Pathol (1989) 0.81

A study of atherosclerotic lesion development in the injured pulmonary arteries of dogs with induced hyperlipemia. Lab Invest (1987) 0.81

Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: cellular and cytokine-mediated effector mechanisms. Eur J Immunol (1997) 0.80

Early arterial injury-induced myointimal proliferation in canine pulmonary arteries. Am J Vet Res (1983) 0.80

In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer (1996) 0.80

P-Selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler Thromb Vasc Biol (2000) 0.80

Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat Oncol Investig (1998) 0.80

Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection. Shock (2001) 0.79

Chlorpromazine inhibits arterial ACAT and reduces arterial cholesterol and cholesteryl ester accumulation in cholesterol-fed rabbits. Arteriosclerosis (1986) 0.79

Direct inhibition of factor VIIa by TFPI and TFPI constructs. J Thromb Haemost (2013) 0.79

In vivo demonstration of enhanced arterial constrictor response to serotonin following focal endothelial cell loss. Exp Mol Pathol (1990) 0.79

Smooth muscle proliferation in chronically injured canine pulmonary arteries is reduced by a potent platelet aggregation inhibitor U-53,059. Thromb Haemost (1985) 0.78

Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost (1995) 0.78

A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay. J Thromb Haemost (2014) 0.78

Soluble P-selectin antagonist mediates rolling velocity and adhesion of leukocytes in acutely inflamed venules. Microcirculation (2001) 0.78

Platelet adhesion and myointimal proliferation in canine pulmonary arteries. Am J Pathol (1981) 0.78

Interaction between canine platelets and adult heartworms: platelet recognition of heartworm surfaces. Am J Vet Res (1986) 0.78

Inhibition of feline collateral vessel development following experimental thrombolic occlusion. Circ Res (1976) 0.78

The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule. Haemophilia (2014) 0.78

Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes. Gene (1996) 0.78

Reduction of ischemic myocardial damage in the dog by lidocaine infusion. Am J Pathol (1977) 0.78

Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs. J Thromb Haemost (2014) 0.77

Immunoreactive macrophage colony-stimulating factor is increased in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits after recombinant human macrophage colony-stimulating factor therapy. Mol Reprod Dev (1997) 0.77

Feline polymorphonuclear leukocytes respond chemotactically to leukotriene B4 and activated serum but not to F-Met-Leu-Phe. Agents Actions (1986) 0.77

Scanning electron microscopy of canine pulmonary arteries and veins. Am J Vet Res (1980) 0.77

The response of canine veins to three types of abdominal surgery: a scanning and transmission electron microscopic study. Surgery (1978) 0.77

Endothelial alterations, deposition of blood elements and increased accumulation of 131I-albumin in canine jugular veins following abdominal surgery. Thromb Res (1978) 0.77

Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α. J Thromb Haemost (2014) 0.76

High level expression of active human prothrombin in a vaccinia virus expression system. Thromb Haemost (1992) 0.76

Patterns of changes of anti-ADAMTS13 after plasma exchange. J Thromb Haemost (2006) 0.76

Effects of stress on blood pressure and cardiac pathology in rats with borderline hypertension. Hypertension (1982) 0.76

Human protein C induces anticoagulation and increased fibrinolytic activity in the cat. Thromb Res (1987) 0.76

Heparin inhibits fibrin, but not leukocytes, in a model of deep-vein thrombosis. J Surg Res (1987) 0.76

Serotonin as a factor in depression of collateral blood flow following experimental arterial thrombosis. J Lab Clin Med (1977) 0.75

Effect of acetylsalicylic acid on vascular damage and myointimal proliferation in canine pulmonary arteries subjected to chronic injury by Dirofilaria immitis. Am J Vet Res (1983) 0.75

Development of novel treatment options for patients with haemophilia. Hamostaseologie (2013) 0.75

Beneficial effects of U-63,557A, a thromboxane synthetase inhibitor, in an ovine model of pregnancy-induced hypertension. Am J Obstet Gynecol (1987) 0.75

Evidence for a small functional pool of serotonin in neurohumoral transmission. Res Commun Chem Pathol Pharmacol (1975) 0.75

Factor IX mutants with enhanced catalytic activity. J Thromb Haemost (2009) 0.75

Improvement of collateral circulation after arterial thrombosis with indomethacin therapy. Thromb Haemost (1980) 0.75

The relationship of serotonin to a motor disorder of Scottish terrier dogs. Life Sci (1974) 0.75

1,4-Dihydronaphthoquinones, hydroindoloquinones, benzofurans, and benzothiophenes as inhibitors of 5-lipoxygenase. Synthesis and structure-activity studies. J Med Chem (1990) 0.75

Postadulticide changes in Dirofilaria immitis-infected Beagles. Am J Vet Res (1983) 0.75

Tolerance and pharmacology of ciprostene, a stable epoprostenol (prostacyclin) analogue in humans. J Clin Pharmacol (1986) 0.75

Depression of collateral blood flow following arterial thrombosis. Thromb Haemost (1977) 0.75

Proliferative and lipid metabolism response to balloon angioplasty in canine renal arteries. J Am Coll Cardiol (1990) 0.75

Treatment of canine dirofilariasis: pulmonary thromboembolism caused by thiacetarsamide--microscopic changes. Am J Vet Res (1983) 0.75

Effect of aspirin on collateral blood flow after experimental thrombosis of the feline aorta. Am J Vet Res (1982) 0.75

Effect of acetylsalicylic acid on pulmonary arteriosclerosis induced by a one-year Dirofilaria immitis infection. Arteriosclerosis (1985) 0.75

Pulmonary thromboembolism during therapy of dirofilariasis with thiacetarsamide: modification with aspirin or prednisolone. Am J Vet Res (1983) 0.75

Leukocyte mediated vein injury and thrombosis is reduced by a lipoxygenase inhibitor. Exp Mol Pathol (1986) 0.75

Effects of lidocaine and epinephrine on myocardial preservation following cardiopulmonary bypass in the dog. J Thorac Cardiovasc Surg (1977) 0.75

Pathophysiological changes associated with stress-induced hypertension in the borderline hypertensive rat. Clin Sci (Lond) (1980) 0.75

Products of tissue injury. Their induction of venous endothelial damage and blood cell adhesion in the dog. Arch Pathol Lab Med (1980) 0.75

Effect of long-term aspirin treatment on platelet adhesion to chronically damaged canine pulmonary arteries. Thromb Haemost (1981) 0.75

Use of ultrasound for noninvasive study of blood vessel responsiveness. Am J Physiol (1987) 0.75